Back to news

AI-Powered Cancer Blood Tests Set the Stage for a Multibillion-Dollar Biotech Breakthrough

Globe Newswire•20/11/2026•08:45 ET
2

Key Highlights

  • ➤Guardant Health (GH) FDA-approved Guardant360 CDx for ESR1-mutated advanced breast cancer
  • ➤Guardant360 CDx trial showed a 56% reduction in progression or death risk
  • ➤GRAIL (GRAL) panel backed Galleri’s benefit-risk profile, voting 6-4 on effectiveness
  • ➤Freenome (FRNM) launched SimpleScreen Lung alongside blood-based colorectal screening
  • ➤DataMEDS AI (MEDS) agreed to acquire Todos’ TBIA cancer blood-test assets, pending court approval

Expert Statements

Gerald Commissiong, Interim Co-CEO of DataMEDS

“The TBIA Cancer AI blood testing platform is a technology that was ahead of its time and now has the opportunity to truly flourish in the AI era.”

Gerald Commissiong, Interim Co-CEO of DataMEDS

“To be able to use a single vial of blood, perform a single data capture experiment in the lab and produce results that can help detect multiple types of cancer from that one blood test is truly transformative.”

Gerald Commissiong, Interim Co-CEO of DataMEDS

“This has the potential to make cancer detection not only less expensive to deploy on a per-cancer-diagnosis basis than existing liquid biopsy and other cancer screening tests, but also more clinically useful because this technology digitizes the immune system and as such may be able to identify and distinguish the body’s response to cancer, even at the earliest carcinoma in situ stage.”

Gerald Commissiong, Interim Co-CEO of DataMEDS

“Earlier detection could open the possibility of its use in routine annual blood testing paradigms that would allow patients to be recommended for confirmatory imaging and biopsy testing much earlier in the disease course where cancers are typically significantly more likely to respond to treatment.”

Gerald Commissiong, Interim Co-CEO of DataMEDS

“We look forward to implementing this technology at our Helomics Cancer AI laboratory in Pittsburgh, Penn., where we will work with our emerging oncologist network to source blood samples, under IRB-approved protocols and with patient consent, from patients whose treating physicians are sending in tumor biopsies for the ChemoFx(®) Assay evaluation, that has been granted two unique CPT codes and has begun to receive coverage decisions, helping us to generate revenue while also generating the necessary data to validate the TBIA Cancer AI blood test to support eventual commercial launch as a Laboratory Developed Test and to advance it through the U.S. Food & Drug Administration (FDA) regulatory process thereafter.”

NEW YORK, Nov. 20, 2026 (GLOBE NEWSWIRE) -- A simple blood test that can detect cancer before symptoms appear is one of the most compelling developments taking shape in modern medicine. Biotechnology companies are now using artificial intelligence, genomic sequencing and advanced blood analysis to identify biological signals associated with breast and colorectal cancer. These tests look for traces of tumor DNA, abnormal DNA patterns and other biomarkers that may reveal cancer earlier than traditional methods. The opportunity is attracting serious attention, and the numbers help explain why. Grand View Research estimates the global multi-cancer early detection market could grow to approximately $4.6 billion by 2033, while the broader liquid biopsy market could reach $32.6 billion over the same period. That represents a substantial commercial opportunity for companies developing accurate, affordable and widely accessible cancer screening technologies. Companies advancing AI-powered cancer detection and next-generation blood testing include: DataMEDS AI Inc. (NASDAQ: MEDS), Guardant Health, Inc. (NASDAQ: GH), GRAIL, Inc. (NASDAQ: GRAL), Natera, Inc. (NASDAQ: NTRA), Freenome, Inc. (NASDAQ: FRNM).

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in